Real-World data shows how lorlatinib fights tough lung cancer
NCT ID NCT06678555
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study reviews medical records of 35 adults with ROS1-positive non-small cell lung cancer that had stopped responding to prior treatments. All participants took lorlatinib pills at home until their cancer progressed. Researchers will measure how long the drug controlled the cancer and how long patients lived, providing real-world evidence on its effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Inc
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.